Hemostemix: Funding, Investors & Team (Sep 2026)
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies for medical conditions. These therapies are developed from the patient's own blood, making it a minimally invasive treatment option. The company's main product, ACP-01, is currently in Phase II clinical trials for critical limb ischemia. In addition to this product, Hemostemix is also working on developing other types of cell products, including bone cell precursors, myocardial cell precursors, and neural cell precursors.
Hemostemix has raised $6.2M across 9 funding rounds on record, the most recent an undisclosed round of $260k announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Hemostemix Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Hemostemix Funding Rounds
Hemostemix raised $250k in an undisclosed round announced in Jan 2023.
8 months later, an undisclosed round of $240k was announced in Sep 2023.
1.4 years later, an undisclosed round of $340k was announced in Feb 2025.
4 months later, an undisclosed round of $350k was announced in Jun 2025.
4 months later, an undisclosed round of $500k was announced in Oct 2025.
2 months later, an undisclosed round of $690k was announced in Dec 2025.
5 months later, an undisclosed round of $730k was announced in May 2026.
1 month later, an undisclosed round of $260k was announced in Jun 2026.
Hemostemix Founders and Leadership Team
Contact details for the Hemostemix team: 2 of 2 have an email address on file.
Start 14-day free trial →Hemostemix Funding Compared to Other Biotechnology Startups
Hemostemix's latest round of $260k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Hemostemix in Biotechnology and Blackfalds
Companies Similar to Hemostemix
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in…
Hemostemix Funding FAQs
What does Hemostemix do?
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies for medical conditions. These therapies are developed from the patient's own blood, making it a minimally invasive treatment option. The company's main product, ACP-01, is currently in Phase II clinical trials for critical limb ischemia. In addition to this product, Hemostemix is also working on developing other types of cell products, including bone cell precursors, myocardial cell precursors, and neural cell precursors.
How much funding has Hemostemix raised?
Hemostemix has raised $6.2M across 9 rounds on record. The most recent is an undisclosed round of $260k announced in Jun 2026.
When did Hemostemix last raise funding?
Hemostemix's most recent funding round on record is an undisclosed round of $260k, announced in Jun 2026.
Who founded Hemostemix?
FundedIQ lists Thomas A Smeenk (Founder) at Hemostemix.
Who is the CEO of Hemostemix?
Thomas Smeenk is listed as CEO at Hemostemix.
Where is Hemostemix headquartered?
Hemostemix is based in Blackfalds, Alberta, Canada.
How many employees does Hemostemix have?
Hemostemix is in the 101-250 employee band.
How does Hemostemix's funding compare to other Biotechnology startups?
Hemostemix's latest round of $260k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Hemostemix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Hemostemix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.